All Quizzes > Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation

Key lung cancer decisions often arise after surgery or chemoradiation. Explore how treatment sequencing, immune-based concepts, patient fatigue, and disease biology shape ongoing care across NSCLC and SCLC.

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q1.A patient with unresectable stage III NSCLC completes concurrent chemoradiation with no progression and improving acute toxicity. Which treatment timing approach has demonstrated clearer survival benefit in clinical trials when immune-based strategies are combined with radiotherapy?
    Scroll for Answer Details

    Correct Answer: D

    Across randomized-trial analyses, consolidation immune-based approaches following chemoradiation have shown stronger survival signals than concurrent-only strategies, making the post–concurrent chemoradiation (cCRT) period a key clinical decision point.

    https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1685963/full

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q2.In patients undergoing multimodal lung cancer treatment, which post-treatment factor most commonly influences readiness to continue along a planned care pathway?
    Scroll for Answer Details

    Correct Answer: C

    Patient-reported fatigue and respiratory symptoms frequently persist after intensive therapy and can shape recovery timelines and tolerance for subsequent treatment phases.

    https://link.springer.com/article/10.1007/s00520-025-09956-y

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q3.From an immune-biology perspective, which mechanism is most relevant after chemoradiation in lung cancer?
    Scroll for Answer Details

    Correct Answer: B

    Radiotherapy and chemoradiation can promote tumor antigen release and immune activation, shaping downstream immune surveillance and disease control.

    https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1554499/full

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q4.Compared with NSCLC, which feature most strongly defines the ongoing clinical challenge in limited-stage small cell lung cancer (LS-SCLC) after chemoradiation?
    Scroll for Answer Details

    Correct Answer: A

    LS-SCLC is characterized by marked early responsiveness to therapy followed by a high risk of early recurrence, distinguishing its post-treatment trajectory from NSCLC.

    https://link.springer.com/article/10.1186/s13045-025-01690-6

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q5.Which factor most helps patients remain engaged during prolonged lung cancer treatment courses involving multiple phases of care?
    Scroll for Answer Details

    Correct Answer: D

    Patient engagement strategies that support understanding of treatment goals, sequencing, and expectations can reduce overwhelm and support sustained participation across care phases.

    https://www.lungcancerjournal.info/article/S0169-5002(25)00376-9/fulltext

  • Lung Cancer Decision Points: Sequencing Care After Surgery and Chemoradiation
    Q6.When immune-based strategies are combined with radiotherapy in lung cancer, which safety signal has been most consistently reported?
    Scroll for Answer Details

    Correct Answer: C

    Published trial-level analyses report higher rates of low-grade pneumonitis or pneumonia with combined approaches, without a consistent increase in severe events across studies, supporting proactive monitoring and shared toxicity discussions.

    https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1685963/full